Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates

Virology Journal

Volumn 7, Issue , 2010, Pages

  Takahashi, Marie Nolle ^a   Rolling, Judith A ^a   Owen, Katherine E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLSORBINIL; ADENOVIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; RECOMBINANT VACCINE; VACCINE; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; SEROTYPE; TRANSGENE; ADENOVIRUS; CELL LINE; CYTOMEGALOVIRUS; GENE VECTOR; GENETICS; HUMAN; PROMOTER REGION;

ADENOVIRIDAE; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; AIDS VACCINES; CELL LINE; CYTOMEGALOVIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENETIC VECTORS; HIV-1; HUMANS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROMOTER REGIONS, GENETIC; TRANSGENES; VACCINES; VACCINES, SYNTHETIC;

EID: 77649145875     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-39     Document Type: Article

References (13)

1. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. FH Priddy, et al. Clin Infect Dis 2008 46 1769 81 10.1086/587993 18433307
2. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. JW Shiver EA Emini, Annu Rev Med 2004 55 355 72 10.1146/annurev.med.55.091902.104344 14746526
3. Validation of a new alternative for determining in vitro potency in vaccines containing Hepatitis B from two different manufacturers. ML Cuervo, et al. Biologicals 2008 36 375 82 10.1016/j.biologicals.2008.06.005 18693036
4. Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines. L Coombes, et al. J Immunol Methods 2009 350 142 9 10.1016/j.jim.2009.09.002 19761770
5. Development and validation of an ELISA for quantitation of bovine viral diarrhea virus antigen in the critical stages of vaccine production. A Pecora, et al. J Virol Methods 2009 162 170 8 10.1016/j.jviromet.2009.07.031 19665482
6. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. C Jogler, et al. J Virol 2006 80 3549 58 10.1128/JVI.80.7.3549-3558.2006 16537623
7. Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency. F Wang, et al. Vaccine 2005 23 4500 8 10.1016/j.vaccine.2005.04.023 16002190
8. A robust approach for the quantitation of viral concentration in an adenoviral vector-based human immunodeficiency virus vaccine by real-time quantitative polymerase chain reaction. L Wang, et al. Hum Gene Ther 2006 17 728 40 10.1089/hum.2006.17.728 16839272
9. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. JW Shiver, et al. Nature 2002 415 331 5 10.1038/415331a 11797011
10. A review of vaccine research and development: meningococcal disease. MP Girard, et al. Vaccine 2006 24 4692 700 10.1016/j.vaccine.2006.03.034 16621189
11. Adenoviral gene delivery for HIV-1 vaccination. T Vanniasinkam HC Ertl, Curr Gene Ther 2005 5 203 12 10.2174/1566523053544236 15853728
12. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. W Bruening, et al. Nucleic Acids Res 1998 26 486 9 10.1093/nar/26.2.486 9421504
13. High adenoviral loads stimulate NF kappaB-dependent gene expression in human vascular smooth muscle cells. GJ Clesham, et al. Gene Ther 1998 5 174 80 10.1038/sj.gt.3300576 9578836